CD8A and neoplasm: Sundar et al., reported that patients with metastatic GC with high AP use expressed lower CD8A, GZMA, and PFR1 levels (151) (cytolytic T-cell activity marker (152, 153)), indicating that AP use in metastatic GC was inversely correlated with anti-tumor immunity.